

# CARB-X 2019 Funding Round 2

- Scope: Vaccines & Biotherapeutics
  - Vaccines
  - Therapeutic and preventative antibodies and fragments
  - Other large molecule biotherapeutics (not direct- or indirect-acting peptides)
  - See next slide for scope in detail
- Expressions of Interest (EOI) accepted online only <https://carb-x.org/apply>
- EOI must be submitted July 8 – July 15, 2019, 5 PM ET

Applying for Round 2?  
Mark your calendar  
July 8 – 15, 2019, 5 PM ET

Round

2



# CARB-X 2019 Funding Round 2 – Vaccines & Biotherapeutics

Vaccines, therapeutic and preventative antibodies and fragments, other large molecule biotherapeutic approaches (not including direct- or indirect-acting peptides) as per the pathogens below. Host-directed approaches are not in scope.

EOI must be submitted online July 8 – July 15, 2019, 5 PM ET. <https://carb-x.org/apply>

Pathogen Scope	Area Scope		
	Prevention	Indirect Tx	Direct Tx*
<i>Acinetobacter baumannii</i> , carbapenem-R	YES	YES	YES
<i>Pseudomonas aeruginosa</i> , carbapenem-R	YES	YES	YES
Enterobacteriaceae, carbapenem-R, 3 <sup>rd</sup> -gen cephalosporin-R (ESBL+)	YES	YES	YES
<i>Enterococcus faecium</i> , vancomycin-R	YES	YES	NO
<i>Staphylococcus aureus</i> , methicillin-R, vancomycin-I/R	YES	YES	NO
<i>Campylobacter</i> spp., fluoroquinolone-R <sup>1</sup>	YES	YES	NO
<i>Salmonellae</i> spp., fluoroquinolone-R <sup>1</sup>	YES	YES	YES
<i>Neisseria gonorrhoeae</i> , 3 <sup>rd</sup> -gen cephalosporin-R, fluoroquinolone-R	YES	YES	YES
<i>Streptococcus pneumoniae</i> , penicillin-NS	YES	YES	NO
<i>Shigella</i> spp., fluoroquinolone-R <sup>1</sup>	YES	YES	YES
Group A <i>Streptococcus</i>	YES	YES	NO
Group B <i>Streptococcus</i>	YES	YES	NO

Tx = therapeutic

\*the spectrum of direct acting products can include Gram-positive pathogens however the program must prioritize the Gram-negative pathogens included in the product's spectrum, as evidenced by the data developed at time of application and the workplan/TPP presented to CARB-X